- Home
- AUPH vs HAPN Comparison
AUPH vs HAPN Comparison
Compare AUPH & HAPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$16.10
Company Overview
Basic Information| Metric | AUPH | HAPN |
|---|---|---|
| Founded | 1993 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUPH | HAPN |
|---|---|---|
| Price | $16.10 | $20.75 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | $67.88 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $7.36 | $19.56 |
| 52 Week High | $19.25 | $20.75 |
Technical Indicators
Market Signals| Indicator | AUPH | HAPN |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | N/A |
| Support Level | $14.37 | N/A |
| Resistance Level | $16.07 | N/A |
| Average True Range (ATR) | 0.80 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 15.08 | 0.00 |
Price Performance
Historical Comparison AUPH
HAPN
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.